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reverses HIV latency in microglial cells
David Alvarez‑Carbonell, Yoelvis Garcia‑Mesa, Stephanie Milne, Biswajit Das, Curtis Dobrowolski, Roxana Rojas 
and Jonathan Karn*
Abstract 
Background: Multiple toll‑like receptors (TLRs) are expressed in cells of the monocytic lineage, including microglia, 
which constitute the major reservoir for human immunodeficiency virus (HIV) infection in the brain. We hypoth‑
esized that TLR receptor mediated responses to inflammatory conditions by microglial cells in the central nervous 
system (CNS) are able to induce latent HIV proviruses, and contribute to the etiology of HIV‑associated neurocognitive 
disorders.
Results: Newly developed human microglial cell lines (hµglia), obtained by immortalizing human primary microglia 
with simian virus‑40 (SV40) large T antigen and the human telomerase reverse transcriptase, were used to gener‑
ate latently infected cells using a single‑round HIV virus carrying a green fluorescence protein reporter (hµglia/HIV, 
clones HC01 and HC69). Treatment of these cells with a panel of TLR ligands showed surprisingly that two potent TLR3 
agonists, poly (I:C) and bacterial ribosomal RNA potently reactivated HIV in hμglia/HIV cells. LPS (TLR4 agonist), flagel‑
lin (TLR5 agonist), and FSL‑1 (TLR6 agonist) reactivated HIV to a lesser extent, while Pam3CSK4 (TLR2/1 agonist) and 
HKLM (TLR2 agonist) only weakly reversed HIV latency in these cells. While agonists for TLR2/1, 4, 5 and 6 reactivated 
HIV through transient NF‑κB induction, poly (I:C), the TLR3 agonist, did not activate NF‑κB, and instead induced the 
virus by a previously unreported mechanism mediated by IRF3. The selective induction of IRF3 by poly (I:C) was con‑
firmed by chromatin immunoprecipitation (ChIP) analysis. In comparison, in latently infected rat‑derived microglial 
cells (hT‑CHME‑5/HIV, clone HC14), poly (I:C), LPS and flagellin were only partially active. The TLR response profile in 
human microglial cells is also distinct from that shown by latently infected monocyte cell lines (THP‑1/HIV, clone HA3, 
U937/HIV, clone HUC5, and SC/HIV, clone HSCC4), where TLR2/1, 4, 5, 6 or 8, but not for TLR3, 7 or 9, reactivated HIV.
Conclusions: TLR signaling, in particular TLR3 activation, can efficiently reactivate HIV transcription in infected 
microglia, but not in monocytes or T cells. The unique response profile of microglial cells to TLR3 is fundamental to 
understanding how the virus responds to continuous microbial exposure, especially during inflammatory episodes, 
that characterizes HIV infection in the CNS.
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Background
Although highly-active anti-retroviral therapies (HAART) 
can reduce circulating virus to below the levels of detec-
tion, these regimens are unable to eliminate residual viral 
infections due to the creation of long-lived reservoirs of 
latently infected cells [1]. The best characterized of these 
reservoirs are the resting memory CD4+ T cells found in 
the peripheral circulation [2, 3]. However, additional cell 
types, including peripheral blood monocytes, dendritic 
cells and macrophages in the lymph node, and astrocytes, 
perivascular macrophages and microglial cells in the 
brain, can also be infected with HIV and can potentially 
contribute to viral persistence [4–8].
Unlike T cells, cells of the monocyte–macrophage lin-
eage are partially resistant to HIV infection due to the 
activity of the SAMHD1 restriction factor [9]. Less than 
1% of the HIV-1 DNA in the peripheral circulation is 
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found in circulating monocytes. Nonetheless, there is 
increasing evidence that myeloid cells facilitate the dis-
semination of the virus and contribute to the persistence 
of viral reservoirs in the CNS [10]. It seems likely that 
perivascular macrophages initiate brain infection, which 
then spreads to resident microglial cell populations 
[10–12]. Analysis of the sequence and phenotypes of 
viruses recovered from the CNS demonstrates that HIV 
in HAND patients represents a distinct, macrophage 
tropic virus population [13–15]. It has been speculated 
that once infected, monocyte–macrophage lineage cells 
are more resistant to certain anti-retroviral drugs and 
the cytopathic and apoptotic effects of HIV than T cells, 
and therefore can harbor actively replicating viruses for 
longer periods even under conditions of effective sup-
pression by HAART. Detection of viral escape mutations 
in the cerebrospinal fluid of individuals under HAART 
with undetectable viral presence in blood supports this 
hypothesis [16–18].
One of the main drivers of HIV infections, and the 
reason why there is chronic inflammation during HIV 
disease, is that damage to the gastrointestinal track 
leads to release of microbial products into the circu-
lation [19]. These potent inducers of inflammatory 
responses are recognized by pattern recognition recep-
tors, including the ten TLRs (TLR1–10), which are 
responsible for the innate recognition of viruses, bac-
teria, fungi, and parasites [20]. Monocytic cells char-
acteristically express most, if not all, of the TLR family 
members, while T cells can only express a more limited 
set of these pattern recognition receptors. In response 
to the presence of pathogens invading the CNS, micro-
glial cells activate their TLRs and initiate CNS innate 
and adaptive immune responses [21]. Excessive and/or 
chronic TLR activation of microglial cells in the brain 
[22] is believed to be directly responsible for a num-
ber of CNS diseases, including chronic HIV encepha-
litis, and the mounting pro-inflammatory reactions in 
response to HIV infections that lead to neurocognitive 
disorders [23, 24].
The signaling pathways following TLR activation 
are complex, and involve a series of protein adaptors 
(MyD88, TIRAP, TRIF, and TRAM) and downstream 
effectors (IRAKs, TRAF6, and TRAF3). In general, TLR 
signaling cascades derived from receptors 2/1, 4, 5, 6, and 
8 eventually lead to the activation of the IKK complex 
and the translocation of the transcription factors NF-κB 
and AP-1 to the nucleus. Alternative pathways to this 
central signaling mechanism result in the production of 
type I interferons (IFNs) and IFN-inducible genes by acti-
vation of IRF7 (TLR7 and 9) and IRF3 (TLR3) [25]. Since 
reactivation of latent HIV proviruses can be potently 
stimulated by NF-κB in many cell types [26–29], TLR 
signaling can potentially lead to enhanced viral replica-
tion in cells that carry the appropriate receptors.
Even though TLR pathways have been relatively well 
characterized, investigations of TLR activation on HIV 
expression in various target cell types have been scarce, 
and largely limited to studies of transformed monocytic 
and T cell lines. Pomerantz et  al. [30] initially reported 
that LPS, a bacterial TLR4 ligand, potently stimulated 
HIV-1 long terminal repeats (LTR) CAT constructs 
transfected into monocyte/macrophage-like cell lines, 
but not a T cell line. Subsequently, LPS-mediated activa-
tion in macrophages was linked to the activity of the PU.1 
and NF-κB transcription factors [31–33], and the direct 
participation of TLR4 in mediating LPS-induced NF-κB 
and HIV-LTR activation was established [32, 33]. Later 
studies using the monocytic THP-1 cells showed that 
TLR2 ligands can also stimulate HIV transcription [33].
An inconsistent set of results has been obtained for the 
other TLR ligands. TLR9 signaling results in increased 
HIV expression in monocytes obtained from transgenic 
mouse spleen cells [33]. However, in latently infected 
ACH-2 T cells, a TLR9 agonist, ODN2006, strongly acti-
vated HIV transcription, but inhibited productive HIV 
infection in MT4 T cells and primary T cells [34]. In a 
model of latently infected mature mast cells, stimulation 
of TLR2, 4 or 9 triggered HIV-1 replication [35]. Thiba-
ult et al. [36] reported that TLR5 stimulation is sufficient 
to trigger reactivation of latent HIV-1 provirus in Jurkat 
T cells and to also activate viral gene expression in cen-
tral memory CD4+ T cells. Consistent with these results, 
Brichacek et  al. [37] found that activation of TLR5, but 
not TLR9, triggers HIV-1 transcription in lymphoid tis-
sue ex vivo. The differential effects of these TLR ligands 
on HIV-1 replication correlated with changes in produc-
tion of CC and CXC chemokines in the ligand-treated 
HIV-1-infected tissues [37]. More recently, Novis et  al. 
reported that Pam3CSK4 (TLR2/1 agonist) leads to viral 
reactivation from latency in cultured central memory T 
(TCM) cells, suggesting a unique pattern of TLR-medi-
ated HIV reactivation in primary T cells [38]. It has been 
known that TLR3 specifically recognizes bacterial riboso-
mal RNA [39], but its role in HIV transcriptional regula-
tion in known.
In this study we investigated the effects of a wide range 
of TLR ligands, including potent TLR2 agonist molecules 
purified from Mycobacterium tuberculosis (Mtb), on the 
reactivation of pro-viral HIV in a novel human model of 
latently-infected microglial cells. Surprisingly, we found 
that TLR3 ligation potently reactivated HIV in microglial 
cells, but not in monocytes or T cells, using an NF-κB-
independent pathway that involves activation of the IRF3 
transcription factor. Additionally, HIV was modestly 
reactivated in human microglial cells by engagement of 
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TLRs 4, 5, and 6. More restricted reactivation patterns 
were observed after stimulation of TLRs 1 and 2, whereas 
no significant reactivation was obtained by activation of 
TLRs 7, 8, or 9. The unique responses of microglial cells 
to TLR ligands provide an important framework for 
understanding how circulating bacterial antigens and 
nucleic acids can enhance HIV replication in microglial 
cells and potentially exacerbate HAND.
Results
Characterization of hµglia/HIV (HC01) and (HC69) cells
The HIV latently-infected cells (hµglia/HIV) used in 
this study were derived from simian virus 40 large T 
antigen (SV40Tag)/human telomerase reverse tran-
scriptase (hTERT)-immortalized human microglial cell 
lines prepared as described by Garcia-Mesa et  al. [40]. 
These novel cell lines, which have characteristic micro-
glial cell phenotypes, have superseded CHME-5 cells in 
our laboratory. CHME-5 cells were originally believed 
to be of human origin [41], and have been widely used 
as models for human microglial cells even until very 
recently [42, 43]. Unfortunately, our detailed molecular 
analyses of CHME-5 proved that they are actually rat 
cells, and were probably derived from a contaminating 
rat glioma [40].
To prepare latently infected cells, we followed a strat-
egy used successfully to create latently infected Jurkat 
T cell lines [44, 45] and CHME-5 cell lines [46]. Briefly, 
as depicted in Fig.  1a, and as extensively explained in 
Garcia-Mesa et  al. [40], commercially-available pri-
mary microglial cells were immortalized through 
infection with vesicular stomatitis virus G (VSV-
G)  envelope pseudotyped viruses expressing SV40Tag 
and hTERT. Immortalized cells (hµglia) were either 
used to isolate clonal populations, such as C20 and 
C06 [40] or infected with a VSV-G pseudotyped len-
tivirus vector (PHR1′/d2EGFP) expressing the short-
lived green fluorescence protein (d2EGFP) as a reporter 
construct (Fig.  2a) to develop clonal populations of 
hµglia/HIV, such as HC01 and HC69. In general, cells 
expressing GFP then were selected by cell sorting. In 
approximately 3–4 weeks, latently infected (GFP−) cells 
begin to outgrow the GFP+ cell population. The two 
clones hµglia/HIV (HC69) and hµglia/HIV (HC01), 
carrying latent proviruses, were then isolated from the 
GFP− population. 
The proviral integration site for each of these two 
clones has been sequenced and located within the host 
genome (Table 1). Both HC01 and HC69 are single inte-
grants and, as expected from the extensive studies char-
acterizing HIV proviral integration sites [44, 47–49], the 
provirus was located in  the introns of host genes. The 
uninfected cell line C20 was used as a negative control, 
where no HIV sequence was detected.
As shown in Fig.  1b, hµglia/HIV cells, exemplified by 
the clone HC01, express the well-established micro-
glial surface markers CD11b and P2RY12 [50]. The cells 
also express the macrophage lineage marker CD14, sug-
gesting that they display an activated phenotype, which 
is consistent with RNA-seq analyses of the hµglia (C20) 
cells [40].
Induction of HIV expression in hµglia/HIV cells
The presence of latent HIV proviruses (Fig.  2a) in indi-
vidual hµglia/HIV clones was confirmed by viral reacti-
vation in the overnight presence of 500 pg/mL of tissue 
necrosis factor α (TNF-α) or 30 µM of the histone dea-
cetylase inhibitor 4b (HDACi 4b) [51]. Induction of GFP 
was monitored by immunofluorescence (Fig. 2b) as well 
as flow cytometry results (Fig.  2c). In these cells, basal 
HIV expression was extremely low, with 1–6% of the cells 
expressing GFP. However, after exposure to TNF-α for 
16 h, HIV was induced in approximately 90% of the HC69 
cells, or 25% of the HC01 cells. Similarly, exposure to 
HDACi 4b resulted in a strong induction of HIV in nearly 
81% of the HC69 cells, or 61% of the HC01 cells. In gen-
eral, HC01 cells displayed a somewhat more restricted 
HIV reactivation profile than HC69 cells (Fig. 2b, c).
Parallel control experiments in monocytic cell lines 
used latently infected THP-1, U937, and SC cells. As 
shown in Additional file 1: Fig. S1, representative clones 
derived from each of these parental monocytic cell lines 
THP-1/HIV (HA3), U937/HIV (HUC5), and SC/HIV 
(HSCC4) cells, as well as Jurkat/HIV 2D10 [44], were 
highly responsive to treatment with 10  ng/mL TNF-α, 
with more than 95% of the HA3, HUC5 and 2D10 cells 
induced to express GFP. The HSCC4 cells were more 
restricted with approximately 50% of the cells expressing 
GFP after TNF-α treatment. There were a wide range of 
responses of these cells to LPS: THP-1/HIV (HA3) cells 
(96%)  >  U937/HIV (HUC5) (53%)  >  SC/HIV (HSCC4) 
(22%)  >  Jurkat/HIV 2D10 (3.5%). As expected, only the 
Jurkat T cells were activated through the TCR (α-CD3/
α-CD28 mAb).
TLR‑mediated HIV reactivation of latently‑infected human 
microglial
Microglial cells are known to express all TLRs at low, 
but detectable, levels [22]. Because engagement of TLRs 
can lead to NF-κB pathway activation, and in turn, HIV 
expression, we assumed that treatment of latently-
infected microglial cells with selective TLR agonists 
would lead to viral reactivation provided there was suf-
ficient receptor expression. However, as described 
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below, microglial cells show specific restrictions in their 
responses to TLR agonists.
Efficient HIV reactivation in the permissive clone HC69 
was achieved by LPS in up to ~73%, by flagellin in up to 
~57% (Figs. 3a, 5a), and FSL-1 in up to ~52% (Fig. 5a). In 
the more restrictive clone HC01, HIV reactivation was 
achieved in the presence of LPS (~17%), flagellin (~13%) 
(Fig. 5a, and Additional file 2: Fig. S2a), and FSL-1 (~21%) 
(Fig. 5a). Pam3CSK4 (~14% in HC69; Fig. 3a, and ~8% in 
HC01; Additional file  2: Fig. S2a) and HKLM (~10% in 
both HC69 and HC01; Fig.  5a) only weakly reactivated 
HIV.
Surprisingly, poly (I:C) very potently reactivated HIV in 
hµglia/HIV (HC69) cells (~80%; Fig. 3a) and significantly 
in hµglia/HIV (HC01) cells (~21%; Additional file 2: Fig. 
S2a). No reactivation was observed with ligands for the 
rest of the TLRs (Fig. 5a).
In comparison, in rat hT-CHME-5/HIV (HC03) cells, 
poly (I:C) (~22%), LPS (~24%), and flagellin (~41%) were 
moderate activators of HIV (Fig. 5a; Additional file 2: Fig. 
S2b). The profile of HIV reactivation by TLR ligands in hT-
CHME-5 (HC14) cells was similar to that of hT-CHME-5 
(HC03) cells, with the exception of poly (I:C), which did 
not reactivated HIV in the HC14 cells (Fig. 5a). Weak or 
no reactivation was observed with the rest of the agonists 
in the rat cells, exemplified here with hT-CHME-5 (HC14) 
(Fig. 5a). In both the human and the rat cells, Mtb-derived 
TLR agonists were ineffective or very weak activators of 
HIV transcription (Additional file 3: Fig. S3a).
As a positive control, we also tested the ability of TLR 
agonists  to induce HIV induction in the monocytic 
cell lines THP-1/HIV (HA3) (Figs.  3b, 4b), U937/HIV 
(HUC5) and SC/HIV cells (HSCC4) (Fig.  4b). In con-
trast to the microglial cells, the monocytic cells were 
unresponsive to poly (I:C) (TLR3 ligand), and both cell 
types were unresponsive to imiquimod (TLR7 ligand) or 
ODN2006 (TLR9 ligand) (Figs.  3b, 5b). Also, ssRNA40 



































Immortalization and cloning scheme
Fig. 1 Isolation and characterization of hµglia/HIV (HC69) cells. a Schematic representation of a typical procedure to develop a microglia/HIV clonal 
cell population such as hµglia/HIV (HC69) cells. Uninfected clonal populations are indicated in grey boxes, and latently‑infected clonal populations 
are indicated in blue boxes. b Immunofluorescence analysis of the human microglial cells hµglia/HIV (HC01). Cells were cultured, fixed, and immu‑
nostained with either anti‑CD11b (green), anti‑CD14 (red) or anti‑P2RY12 (red) conjugated antibodies. Nuclei were stained with DAPI (blue). Merged 
images of nuclei, CD11b and CD14, or nuclei, CD11b and P2RY12 are indicated
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than in monocytes, and HKLM (TLR2 agonist) was 
only effective in THP-1/HIV (HA3) cells and, to a lesser 
extent, in hµglia/HIV (HC69) cells (Fig. 5a, b). In T cells, 
exemplified here by Jurkat/HIV (2D10) and Th17/HIV, 
only flagellin (TLR5 agonist) significantly reactivated 
HIV (Fig. 5c). 
Microglial cells respond poorly to potent TLR2 agonists 
derived from Mtb
Because of the poor responses of microglial cells to clas-
sical TLR2/1 ligands, we decided to also test a set of 
highly potent TLR2 agonists derived from Mtb. Mtb-
derived lipoproteins such as LprG [52] as well as the gly-
colipid lipomannan (LM; [53–55]), but not mannosylated 
lipoarabinomannan (ManLAM; [53]), are potent TLR2 
agonists that trigger pro-inflammatory and microbicidal 
innate immune responses. In addition, the Mtb-derived 
polar glycolipid phosphatidylinositol mannoside (PIM) 6 
(PIM6), but not PIM1,2, triggers TLR2 signaling [56]. PIM6 
(Fig. 3; Additional file 3: Fig. S3) or the other Mtb glycolip-
ids or LprG tested did not reactivate HIV in microglial 
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Fig. 2 HIV emergence from latency in human microglial cell models. a Genome organization of the HIV lentiviral vector. A fragment of HIV‑1pNL4‑3, 
containing Tat, Rev, Env, Vpu and Nef with the reporting gene d2EGFP, is cloned into the pHR’ backbone. The resulted plasmid was used to produce 
the VSVG HIV particles, as described previously [112]. b Fluorescence microscopy analysis of TNF‑α‑ and HDACi 4b‑mediated reactivation of HIV in 
latently‑infected microglial cells [hµglia/HIV (HC69) and (HC01)]. Cells treated with TNF‑α (500 pg/mL) or HDACi 4b (30 µM). c FACS analysis 16 h 
post‑treatment. In these, and subsequent FACS profiles, GFP+ cell populations are indicated in green, and the proportion of GFP‑expressing cells is 
indicated in %
Table 1 Proviral integration sites
Cell Type Clone LTR Tat Number of intergrants Loci Gene name Intron or exon
Microglia HC01 WT H13L 1 chr2:95961496–95961523 ANKRD36C Intron
Microglia HC69 WT H13L 1 chr9:7770778 6–77707849 nGNAQ Intron
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In contrast to microglial cells, HIV was strongly reac-
tivated by PIM6 or LprG in THP-1/HIV (HA3) cells 
(Additional file  3: Fig. S3b) in a dose-dependent man-
ner (Additional file 5: Fig. S5). PIM1,2, LM and ManLAM 
were weak activators of HIV in THP-1/HIV (HA3) cells 
whereas not activators (Additional file 3: Fig. S3). Unex-
pectedly, LM failed to reactivate HIV in THP-1/HIV 
(HA3) cells (Additional file  3: Fig. S3). PIM6 and LprG 
were unable to reactivate HIV in U937/HIV (HUC5) 
or SC/HIV (HSCC4) cells as strongly as in THP-1/HIV 
(HA3) (Additional file 3: Fig. S3), presumably due to the 
limited levels of TLR2 receptor in the former (Additional 
file 4: Fig. S4).
Bacterial rRNA, like poly (I:C) agonists, reactivate HIV 
in hμglia/HIV cells
It is well established that TLR3 is able to response to 
dsRNA, particularly dsRNA of viral origin. The effect 
on TLR3 activation by rRNA from bacteria is less docu-
mented, although some evidence indicates that dsRNA 
isolated from bacterial cultures engages TLR3 signal-
ing [39]. Here, we show that rRNA purified from bacte-
ria (Fig.  4a) reactivated HIV in HC69 cells up to ~50%, 
which is comparable to the reactivation obtained with 
poly (I:C) (both LMW and HMW; ~60–65%) (Fig.  4b). 
MNase digestion of bacterial rRNA at these concentra-
tions resulted in accumulation of small dsRNA fragments 
(Fig. 4a), which still reactivate HIV. By contrast the poly 
(I:C) was completely digested (Fig.  4a) and could not 
reactive HIV (Fig. 4b).
TLR expression on microglial/HIV and monocytic cells does 
not correlate with HIV reactivation
As described above, the HIV-latently infected mono-
cytic cell lines responded more robustly to TLR  stimu-
lation than microglial cells, with the exception of TLR3 
activation by poly (I:C)  (Figs. 3, 5; Additional file 3: Fig. 
S3). Surprisingly, this did not strictly correlate with TLR 
expression patterns.
Because poly (I:C) resulted in an unexpectedly strong 





















































































































































































































Fig. 3 HIV reactivation by TLR agonists in latently‑infected microglial 
cells. Treatment of the hµglia/HIV (HC69) clonal populations with TLR 
ligands. HC69 cells (a) were plated 8 h before no treatment or treat‑
ment with the TLR agonists Pam3CSK4 (1 µg/mL), poly (I:C) (10 µg/
mL), LPS (5 µg/mL), flagellin (5 µg/mL) or PIM6 (5 µg/mL) for 16 h 
prior to measuring GFP expression by FACS analysis. THP‑1/HIV (HA3) 
cells (b) were used as positive control
◂
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confirmed that TLR3 is expressed in both clone HC69 
(Fig.  6a, b) and clone HC01 (Fig.  5b). Although almost 
90% of the THP-1/HIV (HA3) cells expressed TLR3 
(Fig. 5b), they failed to respond to poly (I:C) (Figs. 3b, 5b).
The level of expression of the rest of the individual 
TLRs (TLR1, 2, 4–9) on hµglia/HIV (HC69) and (HC01) 
cells, under normal growth conditions, was measured 
by flow cytometry, using THP-1/HIV (HA3) cells as a 
reference (Fig. 6b). Expression of TLR1 was significantly 
greater on hµglia/HIV (~99%, black and red bars) than on 
THP-1/HIV cells (~76%, blue bar); however, strong HIV 
reactivation by Pam3SCK4 is seen in the monocytes, but 
not in the microglia (Figs.  3, 5). This may be the result 
of the lack of TLR2 expression in microglia (~0.7–4%) 
compared to monocytes (~31%). Approximately 31% of 
THP-1/HIV (HA3) cells were positive for TLR2 expres-
sion, but there was no significant TLR2 expression in 
either HUC5 or HSCC4 cells (Additional file 4: Fig. S4), 
explaining the lack of PIM6- or LprG-mediated HIV 
reactivation (Additional file 3: Fig. S3). The lack of TLR2 
expression is also consistent with the weak responses 
provoked by FSL-1 (TLR2/6 agonist; Fig.  5a, b) on HIV 
reactivation in hµglia/HIV versus monocytes/HIV cells, 
since TLR6 was actually expressed at a higher level 
(~99%) in the microglia than in the monocytes (~82%) 
(Fig. 6b).
Despite the relatively weak responses to LPS (Figs. 3a, 
5a), almost the entire microglial cell population was posi-
tive for TLR4 expression (Fig. 6b). One important obser-
vation when comparing the LPS-responses of the three 
monocytic cell models was that the THP-1 response was 
stronger than U937, which in turn was stronger than SC. 
THP-1 cells were ~98% positive for TLR4 (~96% reac-
tivated HIV by LPS), whereas only ~62% of U937 cells 
(~53% reactivated HIV by LPS) and ~25% of SC cells 
(~22% reactivated HIV by LPS) expressed the receptor 
(Additional file  4: Fig. S4), paralleling the hierarchy of 
responses of these cell types to LPS (Fig. 5b).
hµglia/HIV cells are positive for CD14, as exemplified by 
the HC01 staining (Fig. 1b). CD14 is the TLR4 co-recep-
tor needed for LPS-mediated activation, ruling out the 
possibility that the relatively weak TLR4-mediated HIV 
transcriptional response was due to the absence of CD14. 
Therefore, the expression profiles of TLR4 on hµglia/HIV 
cells did not correlate with the more restricted HIV reac-
tivation induced by LPS compared to monocytes.
A similar situation exists for the TLR5 receptor. A 
greater proportion of the microglial line expressed TLR5 
(~32–53%) compared to the monocytic line (~12%; 
Fig.  6b), but the monocytes, nonetheless, responded 
more robustly to flagellin than the microglial cells.
Both cell types also expressed relatively high lev-
els of TLR7 (Fig.  6b), but neither cell type responded 
to imiquimod (Fig.  5a, b). On the other hand, the high 
level of TLR8 expression on the monocytes (~82%) rela-
tive to the microglia (~9–45%) (Fig. 6b) can explain the 
higher response of HIV reactivation on monocytes by 
ssRNA40 (Fig. 5b). Finally, the differential TLR9 expres-
sion observed between the two microglial cell lines (~1 
vs. ~95%), and compared with the monocytes (~87%) 
(Fig. 6b), does not explain that ODN2009 was not able to 




































HIV Reactivation by Bact. rRNA
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Fig. 4 Effect of bacterial rRNA on HIV reactivation in microglia. a 
Microccocal nuclease (MNase) digestion of TLR3 agonists. Bacterial 
rRNA, poly (I:C) HWM, and poly (I:C) LMW were digested with 2 or 
20 U of MNase. Undigested RNA and the digestion products were 
run on a 0.7% agarose gel. b HIV expression in HC69 cells by TLR3 
agonist. Cells were incubated overnight with rRNA, poly (I:C) HMW, 
and poly (I:C) LMW undigested or digested with indicated doses of 
MNase. Error bars indicate the standard deviation for three or more 
experiments
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Modulation of TLR expression by poly (I:C)
In order to assess the ability to poly (I:C) to modulate 
TLR expression in the context of HIV infection, and 
potentially influence cellular responses to inflammation, 
we measured the effect of poly (I:C) treatment on the 
















































































































































































































Fig. 5 Relative induction (Y‑axis) of HIV transcription by TLR ligands (X‑axis). a Microglial cells are represented by hµglia/HIV (HC01; black bars), 
hµglia/HIV (HC69; red bars), and hT‑CHME‑5/HIV (HC14; blue bars). To compare the different cell lines, the data was normalized to TNF‑α induction 
(100%). b The monocytic cells are represented by THP‑1/HIV (HA3; black bars), U937/HIV (HUC5; red bars), and SC/HIV (HSCC4; blue bars). To compare 
the different cell lines, the data was normalized to TNF‑α induction (100%). c T cells are represented by Jurkat/HIV (2D10; black bars) and Th17/HIV 
(mixed population; red bars). The data was normalized to α‑CD3/CD28 induction levels (100%). Error bars indicate the standard deviation for three or 
more experiments
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and compared it to that on infected cells (HC69.1 and 
HC01) as well as monocytic and T cells (Jurkat) with-
out and with HIV. Cells were serum-starved to reduce 
the overall levels of TLR expression, since they were at 
maximal levels under normal growing conditions (1–5% 
FBS). Poly (I:C) treatment increased the expression of 
TLR3 (from ~40 to 98%) and TLR4 (from ~65 to 97%), 
decreased the expression of TLR7 (from ~70 to 40%), and 
did not affect the expression of TLR5 (Fig. 6c).
In comparison with uninfected microglia (C20), 
cells latently infected with HIV (HC69.1 and HC01), 






































































































































Fig. 6 TLR expression on hµglia/HIV (HC69) and (HC01) cells. a Expression of TLR3 on clone HC69 by immunofluorescence. Cells were cultured, 
fixed, and immunostained with either anti‑CD11b (green) or anti‑TLR3 (red) conjugated antibodies. Nuclei were stained with DAPI (blue). Merged 
images of nuclei, CD11b and TLR3 are indicated. b Flow cytometry analysis quantification of surface expression of TLR1–9 on hµglia/HIV (HC69; 
black bars) and (HC01; red bars) cells. Cells were incubated with antibodies against TLR1–9, or corresponding isotype control. THP‑1/HIV (HA3) cells 
(blue bars) were used as control. c Surface expression of TLR3, 4, 5, and 7 on indicated cell lines. Serum‑starved cells were untreated or treated with 
100 ng/mL of poly (I:C) prior to incubation with antibodies against these TLRs, or corresponding isotype control. Error bars represent the standard 
deviation of three or more experiments
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expression for TLR3, 4, 5 and 7 (Fig. 6c). However, when 
the infected cells were stimulated with poly (I:C), the 
level of TLR3 (HC69.1: from ~50 to 98%; HC01: from 
~50 to 99%), TLR4 (HC69.1: from ~70 to 90%; HC01: 
from ~55 to 99%), and TLR7 (HC69.1: from ~50 to 75%; 
HC01: from ~50 to 70%) increased. The level of TLR5 
only increased in HC01 cells (from ~5 to 75%), but not in 
HC69.1 (remained at ~25%) (Fig. 6c).
A similar analysis was performed in monocytic cells 
(THP-1) with and without HIV in either the presence or 
the absence of poly (I:C) (Fig. 6c). Here, poly (I:C) treat-
ment of uninfected cells (THP-1) increased the expres-
sion of TLR3 (from ~50 to 60%), but not of the other 
three receptors. In comparison with uninfected mono-
cytic cells, cells latently infected with HIV (HA3) dis-
played  similar TLR expression profiles (Fig.  6c). When 
the infected cells were stimulated with poly (I:C), the 
level of all four receptors only slightly increased: TLR3 
from ~50 to 60%, TLR4 from ~80 to 83%, TLR5 from ~5 
to 10%, and TLR7 from ~40 to 45% (Fig. 6c). In T cells, 
using Jurkat as a model, all four receptors were only 
slightly altered in infected cells (2D10), and poly (I:C) 
seemed to play a minor to an insignificant role in modu-
lating the expression of any of these four receptors.
Transient induction of NF‑κB by TLR ligands in microglial 
cells
The HIV LTR carries two tandem NF-κB binding motifs 
[57], which are required for proviral emergence from 
latency in T cells [27, 29], but are dispensable for viral 
growth in most T cell lines [26]. One possible explana-
tion for the inefficient responses of microglial cells to 
TLR ligands is that induction of the NF-κB p65 subu-
nit nuclear translocation is inefficient or short-lived. 
Nuclear NF-κB p65 accumulation was therefore meas-
ured by Western blot analysis following TLR activa-
tion. hµglia/HIV (HC69) and THP-1/HIV (HA3) cells 
were treated with TNF-α (10  ng/mL; positive control), 
Pam3CSK4 (1 µg/mL; TLR2/1), LPS (1 µg/mL; TLR4), or 
poly (I:C) (1 µg/mL; TLR3) and monitored at the 30 min, 
2  h, 8  h, or 16  h time points. The results (Fig.  7) dem-
onstrated that, while TNF-α (Fig. 7b, black square/line) 
and, to a lesser extent LPS (blue triangle/line), strongly 
induced p65 nuclear translocation in hµglia/HIV cells at 
the 0.5 and 2-h time points and again at the later 16-h 
time point, Pam3CSK4 (red circle/line) and poly (I:C) 
(purple triangle/line) only weakly induced p65 nuclear 
translocation at the 16-h time point. In contrast, in 
THP-1/HIV cells treated with TNF-α, Pam3CSK4, or 
LPS, p65 strongly appeared at the 30-min time point 
and remained in the nucleus until the 16-h time point. 
In THP-1/HIV cells, poly (I:C) also failed to recruit p65 
(Fig. 7a, b).
To confirm the requirement for NF-κB in TLR-medi-
ated HIV reactivation in latently-infected microglial 
cells, CHME-5 and THP-1 cells were infected with a 
PHR’ derivative carrying inactivating mutations in the 
NF-κB binding site of the HIV LTR [29] (CHME-5/HIV_
mNF-κB or THP-1/HIV_mNF-κB). As shown by flow 
cytometry analysis (Additional file  5: Fig. S5), flagellin 
was unable to reactivate HIV in either CHME-5/HIV_
mNF-κB or THP-1/HIV_mNF-κB cells, as compared to 
the potent activation achieved in CHME-5/HIV (H1F3) 
or THP-1/HIV (HA3) cells. By contrast, HDACi 4b was 
a potent inducer of the proviruses in both the cells carry-
ing the wild type virus and the cells carrying the mutant 
virus (Additional file 5: Fig. S5).
In complementary control experiments, the reporter 
THP1-XBlue™ cells (Invitrogen), which carry an embry-
onic alkaline phosphatase under the control of a synthetic 
NF-κB-inducible promoter, were used to measure NF-κB 
induction by TLR agonists. The results (Additional file 6: 
Fig. S6a) confirmed that only the TLR agonists that reac-
tivated HIV in THP-1/HIV (HA3) cells induced NF-κB 
activation in a time-dependent manner in THP1-XBlue 
reporter cells; this reactivation was blocked in the presence 
of DRB and flavopiridol, inhibitors of P-TEFb (Additional 
file  6: Fig. S6b; please, read further below). Consistently, 
Western blot analysis of nuclear p65 levels in THP-1/
HIV (HA3) cells treated for 30 min with TNF-α or indi-
cated TLR agonists demonstrated that the  TLR agonists 
that reactivated HIV were those that were able to induce 
NF-κB nuclear recruitment (Additional file 6: Fig. S6c).
Similarly, in THP-1/HIV (HA3) cells, HIV reactivation by 
TLR ligands was effectively blocked using the IKKγ NEMO 
binding domain (NBD) inhibitory peptide, but not the con-
trol peptide (Imgenex, CA) (Additional file 7: Fig. S7a).
Induction of IRF3 in microglial cells by TLR3 ligands
Surprisingly poly (I:C), which reactivated HIV in hµglia/
HIV, but not in THP-1/HIV cells, did not induce p65 
nuclear translocation in any of these cell lines (Fig.  7), 
indicating that an NF-κB-independent pathway is 
involved in TLR3-mediated HIV reactivation in micro-
glial cells. We therefore tested whether poly (I:C) was 
capable of inducing IRF3, which could potentially trigger 
HIV reactivation either directly or indirectly. As shown 
in Fig. 8a, poly (I:C) induced IRF3 nuclear recruitment in 
hµglia/HIV (HC69) cells, but not in THP-1/HIV (HA3) 
cells. In contrast, LPS did not induce IRF3 nuclear trans-
location in either hµglia/HIV (HC69) or THP-1/HIV 
(HA3) cells (Fig. 8a).
To confirm the involvement of IRF3 in HIV induction 
in hµglia/HIV cells, we performed studies with the IRF3 
modulator bufalin. Bufalin is a cardiotonic steroid that 
has been found to potently prevent IRF3 dimerization 
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and nuclear localization [58]. We also tested the PI3-
kinase inhibitors LY294002 and wortmannin, since both 
of these drugs can have indirect effects on IRF3 signal-
ing. For example, LY294002 was found to inhibit LPS- and 
poly (I:C)-mediated IFN-β transcription and secretion, as 
well as IRF3 transcriptional activation and binding to the 
IFN-β promoter in fibroblasts [59]. By contrast, wortman-
nin did not inhibit IFN-β production in these studies [59]. 
Treatment of monocyte-derived dendritic cells (DC) with 
wortmannin or LY294002 enhanced IFN-β expression 
upon TLR3 or TLR4 engagement [60]. In the same study, 
it was reported that wortmannin-treated DC cells exhib-
ited enhanced levels of IKK-α/β phosphorylation and 
IκB-α degradation with a concomitant increase in NF-κB 
nuclear translocation, as well as enhanced NF-κB activity 
induced by TRIF overexpression in HEK 293T cells [60].
As shown in Fig.  8a (right), the nuclear recruitment 
of IRF3 induced by poly (I:C) was blocked by bufalin. 
Bufalin also progressively inhibited HIV reactivation 
in response to poly (I:C) in HC69 cells (Fig.  8b). This 
effect can be seen when either the drug titrated and poly 
(I:C) and LPS are used at fixed concentrations (Fig.  8b, 
left-hand graphs) or when the inducers are titrated and 
bufalin was used at a concentration of 25  nM (Fig.  8b, 
right-hand graphs). As expected, there was no significant 
inhibition of LPS-mediated viral reactivation by bufalin 
(Fig. 8b). Treatment of the cells with the negative control, 
wortmannin, slightly enhanced responses to poly (I:C), 
but had no effect on LPS-mediated HIV reactivation 
(Fig. 8b). Similarly, LY294002 did not significantly inhibit 
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Time course of NF-κB p65 nuclear accumulation
Time (hr)
Fig. 7 Induction of NF‑κB nuclear recruitment by TLR ligands in hµglia/HIV (HC69) cells. a Representative Western blot analysis images of NF‑κB p65 
nuclear recruitment after stimulation. Cells [hµglia/HIV (HC69), and THP‑1/HIV (HA3), as control] were untreated or treated with TNF‑α (10 ng/mL), 
Pam3CSK4 (1 µg/mL), LPS (1 µg/mL) or poly (I:C) (1 µg/mL) for 30 min, 2, 8, or 16 h prior to nuclear extracts (NE) purification. Anti‑SPT5 antibody for 
hµglia/HIV and anti‑TBP antibody for THP‑1/HIV were used as loading control. Molecular weights are indicated at the left of the blots. b Quantifica‑
tion of NF‑κB p65 nuclear recruitment is depicted in the relative p65 band intensity (Y‑axis) versus time (X‑axis) graphs. TNF‑α is shown in black 
squares, Pam3CSK4 in red circles, LPS in blue triangles, and poly (I:C) in purple triangles. Error bar represents the standard deviation of three or more 
experiments



























































































































































































Inhibition of HIV Reactivation
b
Fig. 8 Poly (I:C)‑mediated HIV reactivation in hµglia/HIV (HC69) cells requires IRF3 nuclear recruitment. a Representative Western blot analysis 
images of IRF3 nuclear recruitment after poly (I:C) stimulation. Cells were untreated or treated with poly (I:C) (1 µg/mL), or LPS (1 µg/mL), as nega‑
tive control, for 30 or 90 min prior to nuclear extracts purification. Far right Representative Western blot analysis images of IRF3 nuclear recruitment 
after poly (I:C) stimulation in the absence or presence of bufalin. Cells were untreated or treated with poly (I:C) (1 µg/mL), bufalin (25 nM), or a 
combination of both for 90 min prior to nuclear extracts purification. For all blots, anti‑TBP antibody was used as loading control. Molecular weights 
of IRF3 and TBP are indicated at left. b Pharmacological inhibition of poly (I:C)‑mediated HIV reactivation. Left hµglia/HIV (HC69) cells were untreated 
or pre‑treated with either poly (I:C) (1 µg/mL) or LPS (500 pg/mL) for 30 min prior to addition of inhibitors [bufalin (0, 5, 10, and 25 nM); wortman‑
nin (0, 0.5, 2, and 5 nM); LY294002 (0, 0.5, 2, and 5 µM)]. Right hµglia/HIV (HC69) cells were untreated or pre‑treated with inhibitors [bufalin (25 nM); 
wortmannin (5 µM); LY294002 (5 µM)] for 30 min prior to no‑addition or addition of either poly (I:C) (0, 0.1, 0.5, and 1 µg/mL) or LPS (0, 20, 100, and 
500 pg/mL), as indicated
Page 13 of 25Alvarez‑Carbonell et al. Retrovirology  (2017) 14:9 
IRF3 is recruited to the HIV promoter upon activation 
with poly (I:C)
In light of the involvement of IRF3 in regulating poly 
(I:C)-mediated HIV reactivation in microglial cells, we 
performed chromatin-immunoprecipitation (ChIP) anal-
ysis on HC69 cells untreated or treated with either TNF-α 
(positive control), poly (I:C) or LPS for 30 min (Fig. 9). To 
obtain objective information about the distribution of the 
transcription factors on the HIV proviral DNA we uti-
lized a new ChIP-Seq protocol in which we selected for 
HIV sequences by hybridization prior to sequencing. The 
reads were then mapped to the HIV LTR.
Isolated crosslinked DNA–protein samples were sub-
jected to immunoprecipitation with anti-IRF3 and anti-
NF-κB p65 antibodies. Anti-RNAP II pSer5 antibody 
was used as control. There was minimal RNAP II pSer5 
detected on the HIV LTR in the latently infected cells. 
As expected, RNAP II (Fig.  9b) was recruited to HIV 
promoter in response to TNF-α, poly (I:C) or LPS. The 
RNAP II accumulated at the promoter and promoter 
proximal sites downstream of TAR, which mirrors the 
distribution patterns seen in induced T cells [61].
Upon treatment with poly (I:C) (Fig.  9d), IRF3 is 
recruited to the HIV promoter region (Fig.  9a). IRF3 
accumulated preferentially in the −100 to +200 region, 
suggesting the presence of a binding site in this region. By 
contrast, NF-κB p65 (Fig. 9c) was practically absence at 
the HIV promoter in the presence of poly (I:C).
Treatment with LPS yielded opposite results: the abun-
dance of NF-κB p65 at the HIV promoter, especially in the 
−100 to +1 region (Fig. 9c), which overlaps the two tan-
dem NF-κB binding site in the HIV enhancer, was strongly 
increased after LPS treatment. There was also some accu-
mulation NF-κB p65 in downstream regions, consistent 
with previous reports of transcription factor binding in 
the promoter proximal region in myeloid lineage cells [62, 
63]. As expected from our Western blot analyses (Figs. 7, 
8), LPS treatment did not lead to IRF-3 recruitment.
Treatment with TNF-α strongly induced NF-κB p65 
recruitment (Fig.  9c) to the HIV promoter region but 
recruitment of IRF3 by TNF-α was considerably weaker 
than by poly (I:C) (Fig. 9d).
P‑TEFb components are constitutively expressed 
in microglial cells
Tat-dependent HIV expression is strictly dependent upon 
P-TEFb [27, 64]. Since CycT1, a subunit of P-TEFb, is 
known to be up-regulated during early monocyte differen-
tiation, and then subsequently down-regulated in mature 
macrophages [65], we were concerned that poor responses 
to TLR agonists could be associated with limiting P-TEFb 
levels in microglial cells. There could also potentially be 
upregulation of CycT1 levels in response to TLR activation.
We measured CycT1 levels in hµglia/HIV HC69 and 
HC01 cells, before and after TLR activation. As a control, 
we measured CDK9 levels, the second P-TEFb subunit, 
whose expression is maintained at high levels during 
and after macrophage differentiation [65]. Western blot 
analysis of both cell lines (Fig. 10a) untreated or treated 
with TLR ligands [Pam3CSK4, HKLM, poly (I:C), LPS, 
and flagellin] demonstrated that both CycT1 and CDK9 
were stably and constitutively expressed in these cells. 
In HC69 cells, a slight induction of CycT1 was observed 
(Fig.  10b), especially with Pam3CSK4 (from ~0.4 to 1 
arbitrary units), but in general, not significant augmenta-
tion of P-TEFb by the tested TLR agonists was detected. 
As expected, HIV reactivation in hµglia/HIV (HC01) and 
(HC69) and hT-CHME-5/HIV (HC03) and (HC14) cells 
was impaired by the P-TEFb inhibitors DRB or flavopiri-
dol (Additional file 7: Fig. S7b).
Sensitization of hµglia/HIV (HC01) cells by HDACi 4b, 
but not by pro‑inflammatory stimuli, for TLR‑mediated HIV 
reactivation
Neuronal dysfunction does not correlate with the num-
ber of HIV-infected cells or viral antigens in CNS [66, 67], 
but rather with elevated inflammatory cytokine levels. 
High levels of interleukin (IL)-1β and TNF-α are seen in 
the CNS of patients with HAND [68, 69]. Also, a central 
role for TNF-α, IL-6, and IL-1β in gp120-induced neuro-
inflammation has been demonstrated using a rat model 
[70], where intrathecal administration of gp120 induced 
the expression of these cytokines. In addition, IL-8  has 
been reported to be increased during brain injury and 
neuroinflammation [71], and in human brain-derived 
endothelial cells and astrocytes by Tat [10, 38] and gp120 
[72]. In light of the central role of these interleukins in 
mediating neuroinflammatory responses, we measured 
the ability of IL-1β, IL-6, and IL-8 to induce HIV reac-
tivation in microglial/HIV cells. We found that IL-1β 
(Fig.  11; Additional file  8: Fig. S8), but not IL-6 or IL-8 
(Additional file  8: Fig. S8), induced HIV reactivation in 
hµglia/HIV (HC01) (~20%), hµglia/HIV (HC69) (~72%), 
CHME-5/HIV (H1F3) (~22%), hT-CHME-5/HIV (HC03) 
(~21%), and hT-CHME-5/HIV (HC14) (~38%) cells.
Because hµglia/HIV (HC01) cells showed a more 
restrictive phenotype than hµglia/HIV (HC69) cells 
(Fig.  2), we wanted to determine whether the combina-
tion of pro-inflammatory stimuli with TLR ligands could 
potentiate HIV reactivation. Surprisingly, none of the 
TLR ligands tested, poly (I:C) and imiquimod (Fig.  11a, 
b), or Pam3CSK4 and LPS (Fig.  11c) showed additive 
effects with TNF-α or IL-1β. However, additive effects 
were seen using HDACi 4b in combination with poly 
(I:C) and, to a lesser extent, LPS (Fig.  11). By contrast, 
the negative control, imiquimod, did not increase the 
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responses of HDACi 4b-treated cells. This result suggests 
that chromatin repressive structures on the HIV pro-
moter may limit TLR-mediated HIV transcription.
Discussion
HIV can establish latency in a wide variety of myeloid cell 
types
In order to understand HIV expression regulation in 
the context of pro-inflammatory conditions occurring 
in CNS, we have developed a number of ex vivo models 
of HIV latency in microglial cells and, for comparison, 
in monocytic cell lines. Taking advantage of lentiviral 
reporters, we developed these cellular models represent-
ing three different cell types: hµglia/HIV (HC69) and 
(HC01) (Fig. 5; Additional file 3: Fig. S3) (human micro-
glia); CHME-5/HIV (H1F3) (Additional file  5: Fig. S5), 
hT-CHME-5/HIV (HC03) and (HC14) (Additional file 7: 













































































































































hµglia/HIV (HC01) hµglia/HIV (HC69)
Fig. 10 TLR‑mediated activation and NF‑κB nuclear translocation are not accompanied by significant P‑TEFb production induction in hµglia/HIV 
cells. a Representative Western blot analysis blots of CycT1 and CDK9 expression in whole cell extracts (WCE) from hµglia/HIV (HC01) and (HC69) 
cells treated with TLR agonists. Cells were incubated with indicated TLR agonists (Pam3CSK4 at 1 µg/mL, HKLM at 108 cells/mL, poly (I:C) at 10 µg/
mL, and LPS and flagellin at 5 µg/mL) for 16 prior to WCE preparation and SDS‑PAGE/Western blot analysis with anti‑CycT1 antibody, anti‑CDK9 
antibody, or anti‑Tubulin antibody as loading control. b Bar graph depicts the relative level of CycT1 (black bars) and CDK9 (red bars) expression in 
each clone, with error bars representing the standard deviation of three experiments
(See figure on previous page.) 
Fig. 9 Chromatin immunoprecipitation assays showing the association of RNAP II (pSer5), NF‑kB p65 and IRF3 with the HIV LTR. HC69 cells were 
untreated or treated with TNF‑α (10 ng/mL), poly (I:C) (100 ng/mL) or LPS (10 ng/mL) for 30 min. DNA–protein complexes were extracted from 
formaldehyde‑crosslinked cells. a Schematic representation of the HIV promoter region. b Histograms of sequence reads mapping to the HIV LTR 
representing the distribution and relative abundance of RNAP II pSer5, c p65, d IRF3
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(HUC5) and SC/HIV (HSCC4) (Fig. 5; Additional file 3: 
Fig. S3) (human monocytes); and Jurkat/HIV cells (2D10) 
and primary Th17/HIV (Fig. 5; Additional file 3: Fig. S3) 
(human T cells).
In previous studies of HIV latency in microglial cells, 
we employed the CHME-5 cells [46], which were origi-
nally believed to be of human origin [73]. Unfortunately, 
CHME-5 cells are actually rat cells [40]. To study latency 
in bona fide human microglial cell lines, we have devel-
oped microglial cell lines from human primary glial 
cultures using SV40Tag or SV40Tag/hTERT-immortali-
zation (hµglia; Fig. 1a, and [40]). Subsequently, we used 
the hµglia cells to create HIV-latently infected microglial 
cells (hµglia/HIV). The hµglia cell lines demonstrate a 
microglial phenotype and display surface markers and 
functional properties of primary microglia [40]. In par-
ticular, even after infection with HIV, these cells continue 
to express CD11b and P2RY12 [50] (Fig. 1b).
One important observation is that these microglial 
cell lines showed high level expression of CD14, which 
should be low in resting microglia, suggesting that the 
cells have an activated phenotype [72]. We speculate 
that one unexpected consequence of culturing microglial 
ex  vivo is that it induces and permits sustained expres-
sion of CD14 even in the absent of classical stimuli such 
as TNF-α or IL-1β.
HIV transcriptional control in microglial cells
The HIV promoter is an auto-regulated promoter, which 
requires the Tat protein to stimulate efficient transcrip-
tional elongation. As a result of this feedback mechanism, 
HIV silencing occurs whenever Tat availability falls below 
certain threshold levels needed to sustain transcription 
[27, 74–76]. The decline in Tat levels is typically the result 
of multiple complementary inhibitory mechanisms. 
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Fig. 11 Effect of TLR agonists in combination with pro‑inflammatory stimuli in HIV reactivation in hµglia/HIV (HC01) cells. Flow cytometry analysis 
of the effect of poly (I:C) or imiquimod treatment in combination with TNF‑α or IL‑1β on HIV emergence from latency. a hµglia/HIV (HC01) cells were 
untreated or treated with TNF‑α (500 pg/mL), IL‑1β (100 pg/mL), or HDACi 4b (25 µM) alone or in combination with poly (I:C) (1 µg/mL) or imiqui‑
mod (1 µg/mL) for 16 h prior to measuring GFP‑expressing cells by flow cytometry. Fraction of cells expressing HIV is indicated by %. b Quantifica‑
tion of three or more combinatorial experiments is shown. Control black bars, TNF‑α red bars, IL‑1β blue bars, and HDACi 4b purple bars. Pam3CSK4 at 
1 µg/mL and LPS at 5 µg/mL. Error bars indicate standard deviation of three or more experiments
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factor NF-κB (or in T cells, NFAT) is sequestered in the 
cytoplasm. Second, the LTR acquires heterochromatic 
structures that block the transcription start site [44, 77]. 
Typically, latent proviruses accumulate high levels of his-
tone deacetylases and deactylated histones [78–80], and 
methylated histones [44, 81–83]. Finally, in quiescent T 
cells and monocytic precursors, but not in microglial 
cells, the essential Tat-associated transcription elonga-
tion factor, P-TEFb, is severely reduced because of degra-
dation of CycT1 [65, 84, 85].
Induction of HIV transcription requires reversal of the 
chromatin restrictions, which is typically the result of 
NF-κB induction and binding to its recognition sites in 
the HIV LTR region. Chromatin restrictions appear to 
be particularly important for maintaining HIV latency in 
microglial cells [44, 77–83]. Broad spectrum inhibitors 
of histone deacetylases or histone methylase transferases 
are usually potent inducers of latent proviruses [86, 87]. 
We have shown here that HDACi 4b [51], which is a 
chemically novel histone deacetylase inhibitor, is capable 
of reactivating HIV in the absence of NF-κB induction 
and is one of the most potent activators of HIV transcrip-
tion in the microglial cells that we have evaluated (Fig. 2; 
Additional file 3: Fig. S3 and Additional file 8: Fig. S8). In 
view of these molecular mechanisms, it is not surprising 
that TLRs, which are potent inducers of NF-κB and AP-1, 
are also able to activate HIV transcription in latently 
infected microglial cells.
Unique mechanisms of TLR‑mediated HIV reactivation 
in microglial cells
We tested the ability of agonists for TLR1–9 to reactivate 
HIV in microglia as well as in monocytic and in T cells. 
Surprisingly, only the agonist for TLR3, and to a lesser 
extent for TLR4, 5 and 6, reactivated significantly HIV in 
latently-infected microglial cells (Figs. 3, 4, 5; Additional 
file 2: Fig. S2; Additional file 3: Fig. S3). The agonists for 
TLR4, 5 and 6 induced NF-κB p65 nuclear translocation, 
but the effects were transient and therefore proviral reac-
tivation was inefficient.
The engagement of TLR3 resulted in the strongest HIV 
reactivation in human microglial cells of any of the TLRs 
(Fig. 5). We confirmed that in microglial cells, poly (I:C) 
did not induce the nuclear translocation of p65 (Fig. 7), 
but rather uniquely activated the IRF3 transcription fac-
tor (Figs. 8, 9). HIV reactivation by poly (I:C), but not by 
LPS, was significantly inhibited by the IRF3 activation 
inhibitor bufalin [58] (Fig.  8b), which precluded poly 
(I:C)-mediated IRF3 nuclear recruitment. This is con-
sistent with earlier reports that LPS did not induce IRF3 
nuclear translocation [88]. This suggests that an NF-κB-
independent pathway, utilizing IRF3 activation pathway 
[89], may be responsible for mediating HIV reactivation 
in the presence of poly (I:C). There have been no previ-
ous reports of IRF3 activation of latent HIV proviruses. 
Indeed, the only previous reports of IRF3 effects on HIV 
replication come from Suh et  al. [90], who found that 
ligands for both TLR3 and TLR4 inhibited HIV replica-
tion in microglia in an IRF3-dependent manner due to 
the induction of host restriction factors. Another report 
by Sang et al. [91] also indicated that activation of TLR3 
inhibited SIV infection and replication in macaque 
macrophages through induction of viral restriction fac-
tors. More detailed studies will be needed to distinguish 
between the effects of TLR3 activation on pre-integra-
tion events, subject to host restriction, and post-inte-
gration proviral reactivation events of the type we have 
investigated.
These results were confirmed using ChIP experiments 
(Fig.  9). Treatment with poly (I:C), but not with LPS 
(Fig. 9) led to the selective recruitment of IRF3, but not 
of NF-κB, at the HIV LTR. Transcriptional regulation by 
IRF3 of NF-κB responsive genes has been observed in 
other contexts. For example, Wang et al. [92] showed that 
the expression of the ZAP gene was directly regulated by 
IRF3 following virus infection or stimulation of cells with 
dsRNA or dsDNA, and that interaction with ZAP pro-
moter was not dependent on NF-κB. Similarly, Freaney 
et al. conducted a comprehensive ChIP-seq study, which 
provided a detailed and quantitative genome-wide analy-
sis of transcriptional regulation of the cellular antiviral 
response, and revealed extensive colocalization of IRF3 
and NF-κB during virus infection [93].
TLR3 is activated by double-stranded RNA (dsRNA) 
[94], an intermediate formed by most viruses during their 
replication phase, and functions as a signal to activate 
inflammatory cells [95, 96]. For example, in  vitro tran-
scribed HIV gag mRNA complexed with lipofectin acti-
vates TLR3 [97].
In the context of HIV infections, it is important to 
note that TLR3 responses can also be triggered by bac-
terial and other dsRNAs [97–99]. High levels of circulat-
ing bacterial rRNA, LPS, and other bacterial antigens is a 
hallmark of the chronic immune activation seen in HIV-
infected patients, due to long-term damage to the gut. 
Since LPS and dsRNA can reach the brain, it seems likely 
that they can act in unison to reactivate HIV in infected 
microglial cells and thereby induce neuronal damage.
The signaling pathways initiated by dsRNA/TLR3 dif-
fer between human cells of separate lineages, as well 
as between mouse and human. Lundberg et  al. [100] 
showed that TLR3-induced mechanisms of human pri-
mary dendritic cells, macrophages, endothelial cells, and 
synovial fibroblasts, while expressing TLR3 at compa-
rable levels, differ substantially. For example, poly (I:C) 
induced IP-10 secretion by all cell types, while dendritic 
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cells and macrophages failed to produce TNF-α and IL-6 
and, unexpectedly, TNF-α was secreted only by synovial 
fibroblasts. Interestingly, these findings were specific for 
human cells, and not for murine cells.
Microglial cells are extraordinarily sensitive to activa-
tion by the pro-inflammatory cytokines TNFα or IL-1β, 
and the presence of these cytokines in the CNS correlates 
strongly with the development of HAND [69]. At low 
concentrations, these cytokines are capable of eliciting 
strong HIV responses. Surprisingly, we found no addi-
tive effects, or even cross-talk, between TNF-α or IL-1β, 
and TLR ligands (Fig.  11). However, when we used the 
chromatin-modifying agent HDACi 4b in combination 
with Pam3CSK4, poly (I:C), or LPS, but not imiquimod, 
HIV reactivation was stronger than each of the elements 
individually (Fig.  9). This strongly implies that chroma-
tin remodeling is required for potent TLR-mediated 
responses.
Attenuation of TLR‑mediated activation of latent HIV
The level of TLR-mediated HIV reactivation varies 
widely between the different myeloid and T cell types 
(Fig.  5). Even though microglial cells can express the 
entire spectrum of TLR receptors (Fig. 6; [22]), they are 
relatively inefficient for the reactivation of HIV com-
pared to THP-1 cells. In most cases, the poor responses 
in microglial cells do not correlate with levels of recep-
tor expression. For example, hT-hµglia/HIV (HC01) 
cells express very high levels of CD14 (Fig. 1) and TLR4 
(Fig. 6), but respond poorly to LPS (Fig. 5). In hµglia/HIV 
cells, engagement of TLR4 is able to transiently induce 
NF-κB, as exemplified by clone HC69 (Fig. 7), suggesting 
that specific feedback mechanisms dampen down NF-κB 
responses. By contrast, in monocytic cells the NF-κB 
response is sustained and HIV reactivation is enhanced.
In microglial cells (and astrocytes), unlike in the rest of 
the cells of the immune system, activation of the NF-κB 
pathway not only leads to expression of pro-inflam-
matory genes, but also to the recruitment of repressor 
complexes to the promoter of pro-inflammatory genes 
to prevent the mounting of exacerbated inflammatory 
responses in the brain, which can damage adjacent neu-
rons [101, 102]. We are currently investigating whether 
specific co-repressors are also used to attenuate HIV 
responses to NF-κB in microglial cells.
We have also examined the effect of TLR ligands on 
HIV reactivation in latently-infected T cells. Our results 
demonstrate that activation of TLR5 weakly, but signifi-
cantly, induce HIV expression in latently-infected Jurkat/
HIV (2D10) cells as well as in primary Th17/HIV (Fig. 5). 
This is consistent with previous observations by Thibault 
et al. [36], that TLR5 stimulation is a potent activator of 
latent HIV-1 provirus in Jurkat T cells, and also activates 
virus gene expression in TCM. Novis et al. also reported 
that the TLR2/1 agonist Pam3CSK4 leads to viral reac-
tivation from latency in cultured TCM, but in contrast 
to our results using both Jurkat and primary Th17 cells, 
there is no significant activation of these cells by TLR4 or 
TLR5 agonists [103].
Conclusions
HIV does not infect neurons, but it is frequently found 
in perivascular macrophages and microglia [104]. HIV 
encephalitis correlates with the number of activated 
brain mononuclear phagocytes (both perivascular mac-
rophages and microglia), but not with the amount of 
virus or the number of infected cells [105, 106]. There-
fore, the major role of microglial cells in HAND develop-
ment appears to be neuroinflammatory and neurotoxic, 
which is greatly potentiated by viral proteins shed by viral 
CNS sanctuaries [107].
Our data demonstrate that unique patterns of TLR 
expression and novel signaling cascades create unique 
responses to microbial products by microglial, mono-
cytic, and T cell lineages. In particular, TLR3-mediated 
HIV reactivation by IRF3 in microglial cells is a novel 
pathway, which allows HIV to emerge from latency 
in infected microglia and potentially cause neuronal 
damage.
The TLR pathways may also exacerbate neuronal dam-
age in response to viral proteins and drugs of abuse. 
Recently, El-Hage et  al. [108] have shown that exposure 
to HIV-1 Tat and/or gp120 altered TLR expression in 
astrocytes, providing a clue on how viral proteins may 
interfere with the innate immune response of the CNS to 
HIV-1. Similarly, Dutta et al. [109] showed that morphine 
and HIV Tat, together, can lead to up-regulation of TLR2, 
4 and 9, enhanced pro-inflammatory cytokines (IL-6, 
TNF-α) levels, and neuronal damage.
Since HIV patients characteristically have chronic 
inflammation due to the release of microbial compo-
nents into the circulation, TLR responses in each of 
these cell types is likely to contribute to disease progres-
sion. Manipulation of TLR signaling pathways is likely to 
find applications in strategies for viral eradication and/
or silencing [110], since these receptors are differentially 
engaged in cells of the CNS, the monocyte/macrophage 
lineage, and T cell subsets.
Methods
Development of latently‑infected cells
The human immortalized microglial cells (hµglia) used 
to generate HIV-latently infected cells are described 
in Garcia-Mesa et  al. [40]. HIV infection was then 
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conducted essentially as previously described for 
CHME-5/HIV [46] to obtain mixed and clonal popu-
lations of hµglia/HIV cells. Briefly, infection by spin-
oculation was carried out with vesicular stomatitis 
virus G-(VSVG) pseudotyped lentiviral vectors bear-
ing a fragment of HIV-1pNL4-3, containing Tat, Rev, 
Env, Vpu, and Nef (some cell lines contain an older 
HIV construct carrying no Nef [44]) cloned into the 
pHR’ backbone together with the short-lived green 
fluorescence protein (d2EGFP), as previously shown 
[44, 111]; (Fig. 2a). mNF-κB HIVs, bearing a fragment 
carrying mutations in the NF-κB binding sites on the 
LTR region [29], were used as negative controls. The 
viral particles were produced by the triple transfec-
tion of 293T cells using lipofectamine, and the vec-
tor titer was determined as described previously [46, 
112]. GFP+ cells (mixed and clonal populations) were 
isolated 48 h post-infection by fluorescence-activated 
cell sorting (FACS), further cultured, expanded, and 
allowed to enter into a latent state (stable, low GFP 
expression) for four weeks or more, depending on the 
cell type. hT-CHME-5 cells, described in Garcia-Mesa 
et  al. [40], was used to obtain hT-CHME-5/HIV cells 
by superinfection with HIVs, as above. Routine eval-
uation of HIV latency was performed by treatment 
with TNF-α (Sigma-Aldrich, Cat. # T6674) or HDACi 
4b [51], or any other appropriate stimulator for 16  h 
prior to quantification of GFP+ cells by flow cytometry 
analysis (see below). To keep HIV basal expression low 
(below 5%), latent cells were maintained in 1% FBS (in 
DMEM supplemented with 1× normocin) instead of 
5% FBS.
For producing HIV-latently infected THP-1 (ATCC 
number: TIB-202), U937 (ATCC number: CRL-1593.2), 
and SC (ATCC number: CRL-9855) monocytic cell 
lines, uninfected cells were cultured on a 6-well plate 
at a density of (1 ×  106 cells per well) in RPMI growth 
medium containing 10% fetal bovine serum (FBS), 1% 
penicillin/streptomycin, and 50  nM of 2-mercaptoetha-
nol for THP-1 and U937, or in Iscove’s modified Dul-
becco’s medium with 4  mM  l-glutamine adjusted to 
contain 1.5  g/L sodium bicarbonate and supplemented 
with 50  nM 2-mercaptoethanol, 0.1  mM hypoxanthine 
and 16 µM thymidine, and 10% FBS for SC cells. Infec-
tion was carried out by spinoculation, as described above. 
Latency of HIV provirus was characterized by treat-
ment with TNF-α, LPS (Invivogen, Cat. # tlrl-peklps), or 
α-CD3/α-CD28 mAb (TCR) beads (Invitrogen, Dyna-
beads® Human T-Activator CD3/CD28 11161D) for 
16 h prior to quantification of GFP+ cells by FACS (flow 
cytometry) analysis. Jurkat/HIV (2D10) cells [44] was 
used as control.
Integration site analysis
We basically followed the protocol described in Wu 
et al. [113] with some modifications. Briefly, we digested 
250  ng of isolated genomic DNA (using the Qiagen 
DNeasy Blood and Tissue kit) with MseI and BglII Fast 
Digest restriction endonucleases (ThermoFisher Scien-
tific) in Fast Digest buffer for 5 min at 37 °C, followed by 
heat-inactivation for degree for 10 min at 70 °C. 50 ng of 
the digest was then ligated with 100 ng of phosphorylated 
and annealed MseI linker using Quick Ligation (Ther-
moFisher Scientific) for 5 min at room temperature (per 
manufactures instructions), and then heat-inactivated 
for 10 min at 70  °C. The product was then subjected to 
a first PCR round using the Phusion Flash High Fidelity 
Taq master mix (ThermoFisher Scientific), and follow-
ing a protocol consisting of initial denaturing at 98 °C for 
10 sec (1 cycle), and denaturing at 95 °C for 1 s, anneal-
ing at 56  °C for 5  s and extension at 72  °C for 15  s (25 
cycles). In the reaction mix (20  µL total volume), we 
added 10 µL of 2× Phusion Flash PCR Master mix, 1 µL 
of Fwd HIV-1 3′ LTR Primer (10 µM; AGTGCTTCAA-
GTAGTGTGTGCC), 1 µL of Rvs Linker Primer (10 µM; 
GTAATACGACTCACTATAGGGC), and 5 ng of ligated 
DNA. A second PCR round, using the same master mix, 
was carried out by initial denaturing at 98 °C for 10 s (1 
cycle), and denaturing at 95 °C for 1 s, annealing at 60 °C 
for 5 s and extension at 72 °C for 15 s (25 cycles). In the 
reaction mix (50 µL total volume), we added 25 µL of 2× 
Phusion Flash PCR Master mix, 0.5 µL of Gex-Barcode-A 
Ion Adapter (50 µm), 1 µL of Fwd HIV-1 3′ LTR Primer, 
1  µL of Rvs Linker Primer, and 1  µL of the first round 
PCR product. Finally, the second round PCR product 
was run on a 1.5% agarose gel and sizes from 200 to 350 
were selected for sequencing. 300  pg of DNA was used 
for Ion Torrent sequencing following manufactures pro-
tocol, and the flanking sequences of genomic DNA were 
analyzed using the BLAT alignment tool (http://genome.
ucsc.edu).
Reagents, cell culture, and treatments
TLR ligands (Human TLR1–9 Agonist kit, Invivogen, 
Cat. # tlrl-kithw) were prepared as recommended by 
the manufacturer prior to addition to cell cultures. Safe, 
non-toxic doses of these TLR agonists were chosen by 
the propidium iodide (PI) exclusion method [described 
elsewhere, counting stained (dead) cells with a Cellome-
ter® Vision automatic cell counter (Nexcelom Bioscience, 
MA)], after experimentation with THP-1/HIV (HA3) 
cells for further treatment with the rest of the cell lines 
tested.
For testing NF-κB dependence of TLR ligands-medi-
ated HIV reactivation, cells were pre-treated for 2 h with 
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either 100  µM of IKKγ NEMO binding domain inhibi-
tory peptide, or equivalent amount of the control pep-
tide (Imgenex), prior to incubation with indicated doses 
of TLR ligands for 16 h. Quantification of GFP+ cells by 
flow cytometry followed.
In general, assays on suspension cells (THP-1, U937, 
SC, and Jurkat) were carried out at a density of 1 × 106 
cells per mL, in 96-well plates in a volume of 100  µL. 
Assays on microglial cells (attached) were carried out in 
24-well plates containing 1 × 105 cells per well plated at 
least 8  h prior to treatments. Cell culture maintenance 
was carried out at 37 °C in 5% CO2, and treatments were 
performed under the same conditions for 16  h prior to 
evaluation of viral reactivation by flow cytometry and/or 
fluorescence microscopy.
Flow cytometry and microscopy
Quantification of GFP-expressing cells was carried out by 
fluorescence-activated cell sorting (FACS or flow cytom-
etry) analysis using the LSRFortessa instrument for cell 
sorting, the FACSDiva software (BD, NJ) for data collec-
tion, and the WinList 3D software for data analysis. For 
counting GFP+ cells, treated and untreated cells were 
collected and resuspended in 300 µL of cold PBS.
Further characterization of the newly-developed 
hµglia/HIV cells included measuring the surface expres-
sion of CD11b (BD 553310), P2RY12 (Abcam ab86195) 
and CD14 (eBioscience 12-0149), as well as the expres-
sion of TLR3 (SCBT sc-10740) by fluorescence micros-
copy. For fluorescence microscopy, microglial cells were 
cultured on glass coverslips, treated, and subjected to 
immunofluorescence with anti-CD11b-FITC, anti-CD14-
PE, anti-P2RY12-PE antibodies, or secondary PE-con-
jugated antibody for anti-TLR3 primary antibody to 
detect expression of the target receptors. Briefly, treated 
cells were washed, fixed with 4% paraformaldehyde, and 
permeabilized with 0.1% Triton X-100 prior to incuba-
tion with antibodies for 2  h followed by washing with 
DAPI-containing washing solution for nuclear staining. 
For FACS analysis, used to evaluate surface expression 
of TLR1 (SCBT sc-130896), TLR2 (BD 558318), TLR3 
(SCBT sc-10740), TLR4 (eBioscience 12-9917), TLR5 
(SCBT sc-130897), TLR6 (SCBT sc-30001), TLR7 (SCBT 
sc-30004), TLR8 (SCBT sc-25467), or TLR9 (SCBT 
sc-25468), we used 1  ×  105 cells resuspended in 1  mL 
of cold PBS in the presence of 0.5 µg of the antibody or 
equivalent amount of species-specific isotype control 
antibody for 20  min on ice. For comparative profile of 
TLR expression, we used serum-starved HIV-infected 
or uninfected microglia, monocytic, and T cells, in the 
absence or presence of poly (I:C) (100 ng/mL). TLR bind-
ing to cognate antibody was carried out as described 
above. Appropriate secondary antibodies were used in 
the absence of fluorophore-conjugated primary antibody. 
Cell-antibody complexes were centrifuged, and the pellet 
resuspended in 300 µL of PBS before FACS analysis.
To perform experiments to test TLR3-mediated HIV 
reactivation through pharmacological inhibition, we 
purchased LY294002 (Sigma-Aldrich, L2908), bufa-
lin (Sigma-Aldrich, B0261), and wortmannin (Sigma-
Aldrich, W1628). These compounds were prepared as 
indicated by the manufacturers.
Where applicable, cells were brightfield-photographed 
and imaged for GFP+ fluorescence emission with a Nikon 
TE2000 inverted scope equipped with a DS-QiMc cam-
era and controlled by NIS Elements software (Nikon). 
Images were produced by using the ImageJ software 
(NIH).
Detection of TLR stimulation in THP1‑XBlue™ cells
THP1-XBlue™ cells (Invivogen, Cat. # thpx-sp) were cul-
tured as recommended by the Invivogen protocol. After 
the treatment with the TLR ligands or pre-treatment 
with the CDK inhibitors DRB (10  µM) or flavopiridol 
(30 nM) prior to treatment with TLR ligands, at the doses 
indicated in the Fig. legend, cells were centrifuged at 
1500 rpm for 5 min, while preparing the QUANTI-Blue™ 
following the instructions on the pouch (Invivogen). 
180 µL of resuspended QUANTI-Blue™ was mixed with 
20 µL of cell supernatant in a well of a flat-bottom 96-well 
plate, and incubated at 37 °C for the periods of time indi-
cated (for 4 h in the experiments involving the inhibitors) 
prior to determining the SEAP levels using a spectropho-
tometer at 620–655 nm.
SDS‑PAGE/Western blot analysis
Sodium dodecyl sulfate polyacrylamide gel electropho-
resis (SDS-PAGE)/Western blot analysis (carried out as 
described elsewhere) of NF-κB p65 or IRF3 was used to 
assess pathway activation of NF-κB or IRF3, respectively. 
Briefly, cells were treated with TNF-α or shown TLR 
ligand at the indicated concentration for the indicated 
time period. For this, 7  ×  106 cells per treatment were 
cultured or plated (microglia), and treated as described 
above. After two washings with cold PBS, cells were col-
lected in 500  µL of Buffer A [10  mM Hepes/KOH, pH 
7.9, 1.5  mM MgCl2, 10  mM KCl, 1  mM ethylenediami-
netetraacetic acid (EDTA)] in the presence of phenyl-
methylsulfonyl fluoride (PMSF; 1  mM), dithiothreitol 
(DTT; 1  mM), 0.5% nonyl phenoxypolyethoxylethanol 
(NP-40), and 1× Halt® protease/phosphatase inhibitors 
cocktail (Pierce), and cytoplasmic extracts were recov-
ered in the supernatant after centrifugation at 1500×g for 
10 min at 4  °C. Nuclei were then washed three times in 
Buffer A, and re-suspended in 100 µL of Buffer B (20 mM 
Hepes/KOH, pH 7.9, 25% glycerol, 420 mM NaCl, 1 mM 
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EDTA, 1.5 mM MgCl2) containing PMSF (1 mM), DTT 
(1  mM) and the inhibitors cocktail, and centrifuged at 
20,000×g for 15 min at 4  °C to recover nuclear extracts 
(NE). Protein concentration in NE was measured by 
Bradford assay, and protein solutions were subjected 
to SDS-PAGE/Western blot using the Santa Cruz Bio-
technology antibodies against NF-κB p65 (sc-372), IRF3 
(BD Biosciences #550428), or SPT-5 (sc-28678) or TBP 
(sc-273), as loading controls. These primary antibodies 
were bound by the appropriate IRDye 800CW or 680LT 
secondary antibody, and the membranes were scanned 
and analyzed using the Odyssey® Infrared Imaging Sys-
tem (LI-COR Biosciences, NE). Similarly, expression 
of CycT1 and CDK9 in whole cell extracts (WCE) from 
untreated or treated hµglia/HIV (HC01) and (HC69) cells 
was detected by SDS-PAGE/Western blot using anti-
CycT1 antibody (SCBT sc-10750) or anti-CDK9 antibody 
(SCBT sc-8338), respectively, and anti-tubulin antibody 
as loading control.
Chromatin immunoprecipitation (ChIP)
Sample preparation for ChIP experiments were car-
ried out essentially as previously described [44, 61] with 
minor modifications. For each experimental condition, 
7  ×  106 HC69 cells were plated on a 150-mm diam-
eter plate and incubated overnight. Cells were then left 
untreated or treated with either TNF-α (10  ng/mL), 
poly (I:C) (100  ng/mL) or LPS (10  ng/mL) for 30  min. 
The cells were then cross-linked in 1% formaldehyde, 
incubated for 10  min at ambient temperature, and the 
reaction quenched by adding glycine 1  mM, and fur-
ther incubated for 5 min. After a double wash with cold 
phosphate buffer saline (PBS), cells were collected in 
PBS/Halt® cocktail solution by centrifugation for 5 min 
at 3000×g. The cell pellets were resuspended in 500 µL 
of CE buffer vortexed, and incubated for 10 min on ice. 
Nuclei were collected by centrifugation for 3  min at 
9000×g, and resuspended 250 µL of SDS lysis buffer(1% 
SDS, 10  mM EDTA, 50  mM Tris–HCl, pH 8.1), incu-
bated on ice for 15 min with periodic vortexing, and son-
icated in a water bath using a Biorupter Plus water bath 
sonicator for 20  min (30″ ON/30″ OFF cycles). Under 
these conditions the chromatin was cleaved to between 
100 and 500 bp.
Fragmented chromatin was recovered in the super-
natant after centrifugation for 5 min at 9000×g. 5 µg of 
control IgG or anti-RNAP II pSer5 (ab5131, Abcam), 
anti-NF-κB p65 (C-20, SCB), or anti-IRF3 (BD Bio-
sciences #550428) antibodies were incubated in a blocked 
protein A/G coated plate for 30  min. For each immu-
noprecipitation, 45  µL of the chromatin fractions were 
diluted in 100  µL of IP dilution buffer and added to 
antibody coated well. Antibody binding reactions were 
carried out for 1 h at ambient temperature with 500 rpm 
shaking. After two washes with RIPA buffer (25 mM Tris, 
pH 7–8, 150  mM Na, 0.1% SDS, 0.5% sodium deoxy-
cholate, 1% Triton X-100) and one wash with TE buffer, 
chromatin-IgG complexes were eluted and digested in 
elution/Proteinase K buffer for 30  min at 65  °C. Freed 
DNA was purified with PCR magnetic clean up beads 
(PCR cleanup beads, Axygen).
Chromatin immunoprecipitation library preparation, 
enrichment and sequencing
Following purification, the ChIP DNA was end repaired 
(daTailed). Reactions contained 1× ligase buffer 
(NEB), 1  mM dNTPs (NEB), 6 units of T4 DNA poly-
merase (NEB), 2 units or Klenow (NEB), 20 units of 
T4 Polynucleotide kinase (NEB) and 1.25 units of 
Taq DNA polymerase (NEB) and incubated at 20° for 
30  min followed by 65  °C for an additional 30  min. 
MiFWD (Sense; TCGTCGGCAGCGTCT), (Anti-
sense; GACGCTGCCGACGA) and MiRVS (Sense; 
GTCTCGTGGGCTCGGT), (Antisense; CCGAGCC-
CACGAGAC) adapters were ligated (T4 quick ligase, 
ThermoFisher) on to the end repaired DNA and Ioncode 
barcodes were added to each sample using 35 cycle PCR.
Samples were pooled and HIV was enriched using 
hybridization to biotinylated HIV probes. The probes 
were produced by sonicating the HIV-1pNL4-3 construct 
to generate 500 bp fragments. The probes were then end 
repairing/daTailed using the protocol as described above 
and Biotin-14-dATP was added using terminal trans-
ferase. To enrich for HIV sequences, the pooled barcoded 
library was added to 6× SSC buffer, 500  nM blocking 
oligos (pool of all barcodes), 5 µg Cot-1 DNA and water 
to bring up to 98 µL and incubated for 10 min at 95 °C. 
Immediately after, 100  ng of biotinylated HIV probes 
were added to the sample, vortexed, and the temperature 
was reduced to 65 °C and incubated for 1 h. After hybrid-
ization, the biotinylated probe/HIV library was bound to 
13  µL of washed myOne streptavidin Dynabeads (Ther-
mofisher). Beads were then pelleted on a magnet and 
washed 3 times with 200 µL of Ion Torrent wash buffer. 
Each wash was performed by pipetting up and down 10 
times followed by vortexing for 10  s. The last wash was 
done with 200 µL of ddH2O and then the beads were re-
suspended in 10 µL of fresh ddH2O.
The DNA on the beads were amplified using a BesTaq 
master mix (ABMgood) and primers to the Ion Torrent 
adapters A and trP1 for 35 cycles. The library was size 
selected between 200 and 500 bp using gel electrophore-
sis followed by 1:4 water diluted PCR clean up bead iso-
lation. The enriched library was sequenced using the S5 
Torrent Sequencer using a 540 chip following the manu-
factures protocol.
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Following sequencing, the data were analyzed using the 
Geneious suite of software. Each sample was separated 
based on the Ioncode barcodes, adapters were trimmed 
and each sequence was mapped to a 3′ LTR deleted HIV-
1pNL4-3 genome.
Generation of Mycobacterium tuberculosis (Mtb)‑derived 
compounds
Mtb (H37Rv) fractions and glycolipids from the 
TBVTRM Collection (NIAID, HHSN266200400091c 
contract) were provided by the BEI Resources (Manas-
sas, VA). Cell wall-associated glycolipids were: phos-
phatidylinositol mannosides (PIM1,2, NR-14846; PIM6, 
NR-14847), lipomannan (LM, NR-14850) and lipoarabi-
nomannan (LAM, NR-14848). Full-length LprG (rLprG, 
Rv1411c) was amplified from Mtb H37Rv genomic DNA 
by PCR, cloned in E. coli and expressed in M. smegma-
tis as previously described [114]. Treatment of cells with 
Mtb-derived compounds was carried out for 16 h prior to 
evaluation of HIV reactivation.
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Additional files
Additional file 1: Fig. S1. HIV emerges from latency in monocytic cells. 
TNF‑α‑ and LPS‑mediated reactivation of HIV in latently‑infected THP‑1/
HIV (HA3), U937/HIV (HUC5), and SC/HIV (HSCC4) monocytic cells. Cells 
treated with TNF‑α (10 ng/mL) or LPS (1 µg/mL) were subjected to flow 
cytometry (FACS) analysis 16 h post‑treatment initiation. As in the main 
Figs., in the FACS profiles GFP+ cell populations are shown in bright green, 
and the % of GFP‑expressing cells is indicated. TCR‑mediated reactivation 
as well as Jurkat/HIV 2D10 cells [44] were used as control.
Additional file 2: Fig. S2. HIV reactivation by TLR agonists in latently‑
infected microglial cells: Treatment of human hµglia/HIV (HC01) and rat 
hT‑CHME‑5/HIV (HC03) clonal populations with TLR ligands. Cells were 
plated 8 h before no treatment or treatment with TLR agonists Pam3CSK4 
(1 µg/mL), poly (I:C) (10 µg/mL), LPS (5 µg/mL), flagellin (5 µg/mL) or PIM6 
(5 µg/mL) for 16 h prior to measuring GFP expression by FACS analysis.
Additional file 3: Fig. S3. Compiled data for the relative induction 
(Y‑axis) of Mtb TLR2 ligands and HDAC inhibitor (SAHA or HDACi 4b) 
(X‑axis). For indicated microglial cells (a) and monocytes (b), the data was 
TNF‑α‑normalized. For indicated T cells (c), the data was α‑CD3/CD28‑
normalized. a Microglial cells are represented by hµglia/HIV (HC01; black 
bars), hµglia/HIV (HC69; red bars), and hT‑CHME‑5/HIV (HC14; blue bars). b 
The monocytic cells are represented by THP‑1/HIV (HA3; black bars), U937/
HIV (HUC5; red bars), and SC/HIV (HSCC4; blue bars). c T cells are repre‑
sented by Jurkat/HIV (2D10; black bars) and Th17/HIV (mixed population; 
red bars). Error bars indicate three or more experiments.
Additional file 4: Fig. S4. TLR2 and TLR4 are expressed on monocytic 
cells. Flow cytometry analysis of TLR2 (left column) and TLR4 (right 
column) surface expression on THP‑1/HIV (HA3), U937/HIV (HUC5), and 
SC/HIV (HSCC4) cells. Cells were incubated with anti‑TLR2‑Alexa Fluor 
(red), anti‑TLR4‑PE (blue), or isotype control (grey) antibodies prior to 
FACS analysis. Fraction of cells expressing TLR is depicted in % in the flow 
cytometry profiles.
Additional file 5: Fig. S5. HIV reactivation is impaired in CHME‑5 and 
THP‑1 cells latently‑infected with viruses carrying mutant NF‑κB binding 
sites. HIV expression was induced in a CHME‑5/HIV (H1F3) and CHME‑5/
HIV_mNF‑κB (mixed population), and b THP‑1/HIV (HA3) and THP‑1/
HIV_mNF‑κB (mixed population) cells by flagellin (5 µg/mL for microglia 
and 1 µg/mL for THP‑1) or HDACi 4b (30 µM). Cells were incubated with 
activators for 16 h prior to measuring GFP‑expressing cells by FACS. Frac‑
tion of cells expressing GFP is shown in %.
Additional file 6: Fig. S6. TLR‑mediated HIV reactivation involves the 
NF‑κB pathway and P‑TEFb. a Treatment of the reporter THP1‑XBlue™ cells 
with TLR ligands. THP1‑XBlue™ cells were untreated or incubated (X‑axis) 
with Pam3CSK4 (0.1 µg/mL), HKLM (108 cells/mL), poly (I:C) (10 µg/mL), 
poly (I:C)_LMW (10 µg/mL), LPS (1 µg/mL), flagellin (1 µg/mL), FSL‑1 (1 µg/
mL), imiquimod (10 µg/mL), ssRNA40 (5 µg/mL), or ODN2006 (5 µM) for 
2 (black), 4 (red) or 6 (blue) hours prior to quantification of SEAP released 
into the supernatant upon reaction with the QUANTI‑Blue® reagent by 
spectrophotometry at 620 nm (Optical Density; Y‑axis). b Inhibition of TLR‑
mediated NF‑κB activation. THP1‑XBlue™ cells were untreated (black) or 
pre‑treated with DRB (red; 10 µM) or flavopiridol (blue; 30 nM) for 30 min 
prior to treatment with Pam3CSK4 (0.1 µg/mL), HKLM (108 cells/mL), 
poly (I:C) (10 µg/mL), poly (I:C)_LMW (10 µg/mL), LPS (1 µg/mL), flagellin 
(1 µg/mL), FSL‑1 (1 µg/mL), imiquimod (10 µg/mL), ssRNA40 (5 µg/mL), 
and ODN2006 (5 µM), as shown in the X‑axis, prior to quantification of 
SEAP (Y‑axis). c Nuclear recruitment of NF‑κB p65 in THP‑1/HIV (HA3) cells 
treated with TNF‑α or TLR ligands at doses indicated in a or b above. Rep‑
resentative Western blot analysis with anti‑NF‑κB p65 antibody (anti‑SPT5 
antibody used as loading control) of THP‑1/HIV (HA3) cells nuclear extracts 
purified from cells treated for 30 min prior to NE purification. Molecular 
weight markers are shown in kDa.
Additional file 7: Fig. S7. TLR and PTEF‑b inhibition impairs TLR‑medi‑
ated HIV reactivation. a TLR ligands reactivate HIV in an NF‑κB‑dependent 
manner. Treatment of THP‑1/HIV (HA3) cells with TNF‑α (10 ng/mL) or TLR 
ligands (Pam3CSK4 at 0.1 µg/mL, HKLM at 108 cells/mL, poly (I:C) at 10 µg/
mL, LPS at 1 µ/mL, flagellin at 1 µ/mL, FSL‑1 at 1 µg/mL, imiquimod at 
10 µg/mL, ssRNA40 at 5 µg/mL, and ODN2006 at 5 µM) for 16 h after a 2‑h 
pre‑incubation with either 100 µM of IKKγ NEMO binding domain inhibi‑
tory peptide (red bars; Inh Pep) or equivalent amount of the control pep‑
tide (blue bars; Imgenex) (X‑axis). Y‑axis represents % of GFP‑expressing 
cells after FACS measurements and blue squares % of viable cells after PI 
exclusion quantification (right Y‑axis). Error bars depict the standard devia‑
tion of three different experiments. b Partial inhibition of TNF‑α‑, IL‑1β‑, 
or TLR‑mediated HIV reactivation by P‑TEFb inhibitors. Human hµglia/HIV 
(HC01) and (HC69), and rat hT‑CHME‑5/HIV (HC03) and (HC14) microglial 
cells were untreated (black) or pre‑treated with DRB (red; 10 µM) or 
flavopiridol (blue; 30 nM) for 30 min prior to treatment with TNF‑α (30 ng/
mL), IL‑1β (10 pg/mL), LPS (1 µg/mL), or poly (I:C) (10 µg/mL), as shown in 
the X‑axis, for 16 h prior to quantification of GFP (Y‑axis).
Additional file 8: Fig. S8. IL‑1β, but not IL‑6 or ‑8, reactivates HIV in 
latently infected microglial cells. hµglia/HIV (HC01) (black bars) and HC69 
(red bars), CHME‑5/HIV (H1F3) (blue bars), and hT‑CHME‑5/HIV (HC03) 
(pink bars) and HC14 (green bars) cells were incubated in the absence 
(Untreated) or presence of IL‑1β (5 pg/mL), IL‑6 (5 µg/mL) or IL‑8 (5 µg/
mL), as indicated in the X‑axis, for 16 h prior to measuring GFP expression 
by flow cytometry, indicated in the Y‑axis. Error bars represent standard 
deviation of three different experiments.
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